A Review of Diagnostic Impact of Amyloid Positron Emission Tomography Imaging in Clinical Practice | Zendy

Yejin Kim | Zendy; Paul B. Rosenberg | Zendy; Esther S. Oh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Review of Diagnostic Impact of Amyloid Positron Emission Tomography Imaging in Clinical Practice

Author(s) -

Yejin Kim,

Paul B. Rosenberg,

Esther S. Oh

Publication year - 2018

Publication title -

dementia and geriatric cognitive disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.026

H-Index - 110

eISSN - 1421-9824

pISSN - 1420-8008

DOI - 10.1159/000492151

Subject(s) - positron emission tomography , medicine , neuroimaging , dementia , discontinuation , amyloid (mycology) , radiology , disease , nuclear medicine , pathology , psychiatry

Molecular imaging of brain amyloid for the diagnosis of Alzheimer's disease (AD) using positron emission tomography (PET) has been approved for use in clinical practice by the Food and Drug Administration (FDA) since 2012. However, the clinical utility and diagnostic impact of amyloid PET imaging remain controversial. We conducted a review of the recent studies investigating clinical utility of amyloid PET imaging with focus on changes in diagnosis, diagnostic confidence, and patient management.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research